SVB Leerink and AstraZeneca

Selected healthcare news for the capital firm - SVB Leerink, and the company - AstraZeneca. We have 102 shared news items for this connection to-date.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
1/11/2022 Short Interest in AstraZeneca PLC (NASDAQ:AZN) Declines By 16.8% - Mayfield Recorder Mayfield Recorder AstraZeneca PLC (NASDAQ:AZN) was the recipient of a large drop in short interest during the month of December. As of December 15th, there was short interest totalling 6,280,000 shares, a drop of 16.8% from ... of AstraZeneca in a research note on Tuesday, October 19th. SVB Leerink reaffirmed a ‚Aubuy‚Au rating on shares of AstraZeneca in a report on Sunday, December 12th. Deutsche Bank Aktiengesellschaft reaffirmed a ‚Aubuy‚Au ...
12/7/2021 Watch out, Pfizer and Alnylam. AstraZeneca wades deeper into rare diseases with Ionis tie-up | FiercePharma FiercePharma Just months after wrapping up the Alexion acquisition, AstraZeneca is beefing up its newly established rare disease portfolio with a collaboration with Ionis Pharmaceuticals, targeting a condition where Pfizer and Alnylam are also competing.For ... Street thinks eplontersen can generate $1.3 billion in 2030 sales, SVB Leerink analyst Mani Foroohar said in an October note to clients.An estimated 300,000 to 500,000 patients have ATTR around the globe, according to ...
10/1/2021 Is the cancer immunotherapy market up for disruption as AstraZeneca, Regeneron-Sanofi, cheaper Chinese offerings line up? ... AstraZeneca, a partnership between Regeneron and Sanofi plus several Chinese firms and their Western collaborators are all lining up their products for the most desirable piece of the cake: non-small cell lung cancer. Some new players are touting what they say are comparable efficacy data as Keytruda‚Aos, while the Chinese newcomers plan to disrupt the PD-1/L1 space with lower prices. But as SVB Leerink‚Aos immuno ...
10/1/2021 Is the cancer immunotherapy market up for disruption as AstraZeneca, Regeneron-Sanofi, cheaper Chinese offerings line up? FiercePharma ... AstraZeneca, a partnership between Regeneron and Sanofi plus several Chinese firms and their Western collaborators are all lining up their products for the most desirable piece of the cake: non-small cell lung cancer (NSCLC).Some new players are touting what they say are comparable efficacy data to Keytruda‚Aos, while the Chinese newcomers plan to disrupt the PD-1/L1 space with lower prices. But as SVB Leerink‚Aos ...
9/30/2021 Equities Analysts Offer Predictions for AstraZeneca PLC's Q3 2021 Earnings (NASDAQ:AZN) AstraZeneca PLC (NASDAQ:AZN) ‚Ai Equities researchers at Jefferies Financial Group issued their Q3 2021 EPS estimates for AstraZeneca in a report issued on Tuesday, September 28th. Jefferies Financial Group analyst P. Welford forecasts that ... 12th. They set an ‚Auoverweight‚Au rating for the company. SVB Leerink boosted their price objective on shares of AstraZeneca from $71.00 to $73.00 and gave the company an ‚Auoutperform‚Au rating in a research ...
9/29/2021 AstraZeneca (NASDAQ:AZN) PT Raised to $73.00 - The Cerbat Gem AstraZeneca (NASDAQ:AZN) had its price target upped by equities research analysts at SVB Leerink from $71.00 to $73.00 in a note issued to investors on Monday, Benzinga reports. The firm presently has an ‚Auoutperform‚Au rating on the stock. SVB Leerink‚Aos target price would suggest a potential upside of 26.67% from the company‚Aos current price. SVB Leerink also issued estimates for AstraZeneca‚Aos Q3 2021 earnings at ...
9/22/2021 FY2024 EPS Estimates for AstraZeneca PLC (NASDAQ:AZN) Raised by Analyst AstraZeneca PLC (NASDAQ:AZN) ‚Ai Equities researchers at SVB Leerink boosted their FY2024 EPS estimates for shares of AstraZeneca in a research note issued to investors on Monday, September 20th. SVB Leerink analyst A. Berens now forecasts that the company will post earnings of $4.43 per share for the year, up from their prior forecast of $4.42. SVB Leerink currently has a ‚AuOutperform‚Au rating and a $71.00 price target ...
9/21/2021 AstraZeneca (NASDAQ:AZN) Given New $71.00 Price Target at SVB Leerink Dakota Financial News AstraZeneca (NASDAQ:AZN) had its target price hoisted by SVB Leerink from $69.00 to $71.00 in a report issued on Monday morning, Benzinga reports. SVB Leerink currently has an outperform rating on the stock. AZN has been the subject of several other reports. Morgan Stanley reiterated an overweight rating on shares of AstraZeneca in a research report on Friday. JPMorgan Chase & Co. assumed coverage on AstraZeneca in a research report ...
9/21/2021 AstraZeneca (NASDAQ:AZN) Shares Gap Up Following Analyst Upgrade - Mayfield Recorder Mayfield Recorder AstraZeneca PLC (NASDAQ:AZN)‚Aos stock price gapped up prior to trading on Monday after SVB Leerink raised their price target on the stock from $69.00 to $71.00. The stock had previously closed at $55.56, but opened at $56.86. SVB Leerink currently has an outperform rating on the stock. AstraZeneca shares last traded at $56.79, with a volume of 87,330 shares traded.AZN has been the topic of a number ...
9/21/2021 AstraZeneca's (AZN) Overweight Rating Reiterated at Morgan Stanley Morgan Stanley reaffirmed their overweight rating on shares of AstraZeneca (NASDAQ:AZN) in a research report sent to investors on Friday morning, The Fly reports. A number of other brokerages also recently issued reports on ... 12th. They issued an overweight rating on the stock. Finally, SVB Leerink raised their price target on AstraZeneca from $63.00 to $69.00 and gave the company an outperform rating in a research report on Wednesday ...
9/21/2021 Morgan Stanley Reaffirms Overweight Rating for AstraZeneca (NASDAQ:AZN) Morgan Stanley restated their overweight rating on shares of AstraZeneca (NASDAQ:AZN) in a research note issued to investors on Friday morning, The Fly reports. Other equities analysts have also issued research reports about the company. Citigroup reaffirmed a buy rating on shares of AstraZeneca in a research note on Wednesday, July 21st. SVB Leerink increased their target price on AstraZeneca from $63.00 to $69.00 and gave the company an ...
9/21/2021 AstraZeneca (NASDAQ:AZN) Shares Gap Up on Analyst Upgrade Shares of AstraZeneca PLC (NASDAQ:AZN) gapped up before the market opened on Monday after SVB Leerink raised their price target on the stock from $69.00 to $71.00. The stock had previously closed at $55.56, but opened at $56.86. SVB Leerink currently has an outperform rating on the stock. AstraZeneca shares last traded at $56.79, with a volume of 87,330 shares. A number of other analysts have also recently issued ...
9/20/2021 Why AstraZeneca Shares Are Trading Higher Today Benzinga AstraZeneca PLC (NASDAQ: AZN ) is trading higher Monday after the company announced its Enhertu data that was presented at the European Society for Medical Oncology showed reduced risk of disease progression by 72% in patients ... therapeutic classes including gastrointestinal, diabetes, cardiovascular, respiratory, cancer and immunology. SVB Leerink analyst Andrew Berens maintained AstraZeneca with an Outperform rating and raised the price target from $69 to $71. AZN Price Action: AstraZeneca has ...
9/19/2021 AstraZeneca (NASDAQ:AZN) Earns Overweight Rating from Morgan Stanley AstraZeneca (NASDAQ:AZN)‚Aos stock had its ‚Auoverweight‚Au rating restated by stock analysts at Morgan Stanley in a report issued on Friday, The Fly reports.A number of other research firms also recently weighed ... of AstraZeneca in a research note on Wednesday, July 21st. SVB Leerink boosted their target price on shares of AstraZeneca from $63.00 to $69.00 and gave the company an ‚Auoutperform‚Au rating in a research ...
9/17/2021 What Is Happening With Innate Pharma Stock On Friday? Benzinga Innate Pharma SA (NASDAQ: [IPHA] ) stock is trading at a 52-week high as its partner AstraZeneca Plc (NASDAQ: [AZN] ) presented results from the COAST Phase 2 trial during the European Society for Medical Oncology ... study with monalizumab plus durvalumab in the same indication. - Also, SVB Leerink maintained an Outperform on IPHA and raised its price target from $7 to $9. - Earlier this month, analyst Daina Graybosch upgraded Innate to ...
9/14/2021 AstraZeneca PLC (NASDAQ:AZN) Receives $122.00 Consensus Price Target from Analysts - The Cerbat Gem Shares of AstraZeneca PLC (NASDAQ:AZN) have been given a consensus rating of ‚AuBuy‚Au by the fifteen brokerages that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a ... 9th. They issued an ‚Auoverweight‚Au rating for the company. SVB Leerink lifted their price target on shares of AstraZeneca from $63.00 to $69.00 and gave the company an ‚Auoutperform‚Au rating in a research ...
9/14/2021 AstraZeneca PLC (NASDAQ:AZN) Receives Average Rating of ‚ÄúBuy‚Äù from Brokerages - Watch List News Shares of AstraZeneca PLC (NASDAQ:AZN) have received a consensus rating of ‚AuBuy‚Au from the fifteen research firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock ... shares of AstraZeneca in a report on Wednesday, July 21st. SVB Leerink upped their price target on shares of AstraZeneca from $63.00 to $69.00 and gave the company an ‚Auoutperform‚Au rating in a report ...
9/9/2021 The Allstate Co. (NYSE:ALL) Holdings Lifted by O Shaughnessy Asset Management LLC | Daily Political Daily Political AstraZeneca PLC (NASDAQ:AZN) Receives $122.00 Consensus PT from Analysts Posted by Stacy Sanders on Sep 9th, 2021 Share on StocktwitsShares of AstraZeneca PLC (NASDAQ:AZN) have been assigned a consensus rating of ‚AuBuy ... of AstraZeneca in a research note on Wednesday, July 21st. SVB Leerink lifted their target price on shares of AstraZeneca from $63.00 to $69.00 and gave the company an ‚Auoutperform‚Au rating in a research ...
9/9/2021 AstraZeneca PLC (NASDAQ:AZN) Receives $122.00 Consensus PT from Brokerages AstraZeneca PLC (NASDAQ:AZN) has received a consensus rating of ‚AuBuy‚Au from the fifteen brokerages that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two ... Several equities analysts have recently issued reports on the company. SVB Leerink lifted their price target on AstraZeneca from $63.00 to $69.00 and gave the stock an ‚Auoutperform‚Au rating in a research report on ...
9/8/2021 GSK, Pfizer and Johnson & Johnson race toward $10B+ RSV vaccine market: analyst FiercePharma ... high-profile trial failures over the years, vaccines are now advancing through late-stage testing and could launch in 2023, SVB Leerink analyst Geoffrey Porges wrote to clients this week.As companies race to the ... with its late-stage RSV program. The company and partner AstraZeneca are working on a prophylactic monoclonal antibody for infants, and they plan to file for approval next year.Other vaccine and drug developers including ...
9/6/2021 AstraZeneca PLC (NASDAQ:AZN) Receives Average Recommendation of ‚ÄúBuy‚Äù from Brokerages AstraZeneca PLC (NASDAQ:AZN) has been given a consensus rating of ‚AuBuy‚Au by the fifteen analysts that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a ... 12th. They issued an ‚Auoverweight‚Au rating on the stock. SVB Leerink raised their price target on AstraZeneca from $63.00 to $69.00 and gave the company an ‚Auoutperform‚Au rating in a report on Wednesday ...
9/6/2021 AstraZeneca PLC (NASDAQ:AZN) Receives Average Recommendation of ‚ÄúBuy‚Äù from Analysts AstraZeneca PLC (NASDAQ:AZN) has received an average recommendation of ‚AuBuy‚Au from the fifteen brokerages that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell ... They issued an ‚Auoverweight‚Au rating on the stock. Finally, SVB Leerink lifted their target price on AstraZeneca from $63.00 to $69.00 and gave the company an ‚Auoutperform‚Au rating in a research note on ...
8/30/2021 Financial Advocates Investment Management Makes New Investment in AstraZeneca PLC (NASDAQ:AZN) - Transcript Daily Financial Advocates Investment Management bought a new position in shares of AstraZeneca PLC (NASDAQ:AZN) during the second quarter, Holdings Channel.com reports. The firm bought 3,443 shares of the company‚Aos stock, valued at approximately ... AZN has been the topic of several recent research reports. SVB Leerink upped their price target on AstraZeneca from $63.00 to $69.00 and gave the stock an ‚Auoutperform‚Au rating in a research note on ...
8/20/2021 AstraZeneca's Alexion buy takes first hit as Ultomiris fails in rare neurodegenerative disease FiercePharma Bad news has struck first for AstraZeneca‚Aos newly acquired Alexion rare disease franchise.AstraZeneca has decided to cap a phase 3 trial testing C5 inhibitor Ultomiris in the rare neurodegenerative disease amyotrophic lateral sclerosis ... trial before Alexion launched the phase 3 Champion-ALS study, SVB Leerink analyst Andrew Berens pointed out in a note to investors in December. With that, ALS has always remained an uncertain commercial opportunity for ...
8/16/2021 FibroGen's longtime CFO hands baton to J&J veteran as high-profile roxadustat blowup cues a likely overhaul FiercePharma ... another C-level executive. The latest transition comes as the San Francisco biotech grapples with the FDA rejection of its AstraZeneca-partnered anemia drug roxadustat.Pat Cotroneo, who joined FibroGen in 2000 and has been ... in the U.S., FibroGen needs a restructuring to sustain itself, SVB Leerink analyst Geoffrey Porges said in a note to clients after the roxa rebuff.Another drug in development at the biotech, pamrevlumab, is currently ...